LEADER 03888nam  2200589   450 
001 9910787716503321
005 20230803032224.0
010   $a0-309-28482-1
010   $a0-309-28480-5
035   $a(CKB)2670000000517633
035   $a(EBL)3379201
035   $a(SSID)ssj0001215951
035   $a(PQKBManifestationID)11792098
035   $a(PQKBTitleCode)TC0001215951
035   $a(PQKBWorkID)11179331
035   $a(PQKB)10306460
035   $a(MiAaPQ)EBC3379201
035   $a(Au-PeEL)EBL3379201
035   $a(CaPaEBR)ebr10863855
035   $a(OCoLC)862117649
035   $a(EXLCZ)992670000000517633
100   $a20140505h20132013  ua|            0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt
182   $cc
183   $acr
200 00$aInternational regulatory harmonization amid globalization of drug development $eworkshop summary /$fVictoria Weisfeld and Tracy A. Lustig, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy
210  1$aWashington, District of Columbia :$cNational Academies Press,$d[2013]
210  4$dİ2013
215   $a1 online resource (128 p.)
300   $aDescription based upon print version of record.
311   $a0-309-28479-1 
320   $aIncludes bibliographical references.
327   $a""Front Matter""; ""Reviewers""; ""Contents""; ""Boxes""; ""Acronyms""; ""1 Introduction""; ""2 Principles and Definitional Considerations""; ""3 Overview of the Current Global Regulatory Landscape""; ""4 Areas of Need for Harmonized Standards and Barriers to Progress in Addressing the Gaps""; ""5 Characteristics of Harmonized Regulations and Regulatory Structures""; ""6 Finding Solutions: Options and Systemic Approaches""; ""7 Tactics and Strategies for a Way Forward""; ""References""; ""Appendix A: Workshop Agenda""; ""Appendix B: Participant Biographies""
330   $a"The past several decades have been a time of rapid globalization in the development, manufacture, marketing, and distribution of medical products and technologies. Increasingly, research on the safety and effectiveness of new drugs is being conducted in countries with little experience in regulation of medical product development. Demand has been increasing for globally harmonized, science-based standards for the development and evaluation of the safety, quality, and efficacy of medical products. Consistency of such standards could improve the efficiency and clarity of the drug development and evaluation process and, ultimately, promote and enhance product quality and the public health.  To explore the need and prospects for greater international regulatory harmonization for drug development, the IOM Forum on Drug Discovery, Development, and Translation hosted a workshop on February 13-14, 2013. Discussions at the workshop helped identify principles, potential approaches, and strategies to advance the development or evolution of more harmonized regulatory standards. This document summarizes the workshop"--$cPublisher's description.
606   $aDrug development$vCongresses
615  0$aDrug development
676   $a615.19
700   $aWeisfeld$b Victoria D.$0898935
702   $aWeissfield$b Victoria
702   $aLustig$b Tracy A.
712 02$aInstitute of Medicine (U.S.).$bForum on Drug Discovery, Development, and Translation,
712 02$aInstitute of Medicine (U.S.).$bBoard on Health Sciences Policy,
712 12$aInternational Regulatory Harmonization Amid Globalization of Biomedical Research and Medical Product Development (Workshop)$f(2013 :$eWashington, D.C.),$bsponsoring body.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910787716503321
996   $aInternational regulatory harmonization amid globalization of drug development$93695929
997   $aUNINA